SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: (Original Filing)
[SKYSTARMMENCES TESTING ON TWODITIONAL NEW PRODUCT DOSAGE FORMS TO FURTHER EXPAND THEMPANYS PRODUCT LINES The new dosage forms projected to generate $5 million inditional revenue by fiscal 2011 XI'AN, CHINA May 12, 2010 -ystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) ("Skystar" or the "Company"), The product testing process will ensure that the new dosage forms willhere to good manufacturing]
